Background: To evaluate whether the addition of taxanes to platinum and fluoropyrimidines in adjuvant chemotherapy would result in longer survival than platinum plus fluoropyrimidines in gastric cancer patients who received D2 gastrectomy.
Methods: Data of patients with gastric adenocarcinoma who received D2 gastrectomy and adjuvant chemotherapy with platinum plus fluoropyrimidines or taxanes, platinum plus fluoropyrimidines was retrospectively collected and analyzed. 1:1 Propensity score matching analysis was used to balance baseline characteristics between two groups. Survival curves were estimated using Kaplan-Meier method, and the differences were compared using the log-rank test.
Results: Four hundred twenty-five patients in the platinum plus fluoropyrimidines group and 177 patients in the taxanes, platinum plus fluoropyrimidines group were included into analysis. No statistical differences in disease-free survival and overall survival were observed between two groups. After propensity score matching, 172 couples of patients were matched, the baseline characteristics were balanced. The median disease-free survival were 15.8 months (95% CI, 9.3~22.4) in the platinum plus fluoropyrimidines group and 22.6 months (95% CI, 15.9~29.4) in the taxanes, platinum plus fluoropyrimidines group (HR = 0.63; 95% CI, 0.48~0.85; P = 0.002). The median overall survival was 25.4 months for patients in the platinum plus fluoropyrimidines group (95% CI, 19.4~31.3) and 33.8 months (95% CI, 23.5~44.2) for those in the taxanes, platinum plus fluoropyrimidines group (HR = 0.68; 95% CI, 0.53-0.87; log-rank test, P = 0.002).
Conclusions: For gastric adenocarcinoma patients, the adjuvant triplet combination of taxanes, platinum, and fluoropyrimidines regimen after D2 gastrectomy was superior to platinum plus fluoropyrimidines regimen in disease-free survival as well as overall survival.
Trial Registration: This project has been registered in the Chinese Clinical Trial Registry ( ChiCTR1800019978 ).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434742 | PMC |
| http://dx.doi.org/10.1186/s12957-021-02390-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.
Oncologist
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan.
Purpose: Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC.
View Article and Find Full Text PDFChemotherapy and radiotherapy for advanced pancreatic cancer.
Cochrane Database Syst Rev
December 2024
Medical Oncology, The Kinghorn Cancer Care Centre, St Vincent's Hospital, Sydney, Australia.
Article Synopsis
- Pancreatic cancer is a highly lethal disease with limited treatment options, leading to an updated review of randomized data focused on first-line treatments for advanced cases.
- The review examines the impact of chemotherapy, radiotherapy, or a combination of both on overall survival, severe adverse events, and quality of life for patients with unresectable or metastatic pancreatic cancer.
- A total of 75 studies were analyzed, with 51 included in the meta-analysis, examining various treatment comparisons and finding that the studies generally had low risks for biases in methodology.
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer.
ESMO Open
December 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Department of Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Background: This study aimed to investigate the prevalence of claudin 18.2 (CLDN18.2) positivity, with a particular focus on intratumoral heterogeneity, and its association with clinicopathological features in metastatic or unresectable gastric cancer (GC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!